Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as ...
Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 ...
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated ...
Gossamer Bio (NASDAQ:GOSS) reported top-line results from PROSERA, its global phase III registrational study evaluating ...
CNW/ - ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical ...
Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic dermatitis, where the candidate successfully reduced the size and ...
WASHINGTON (AP) — The United States said Wednesday that it is moving into the next phase of a Gaza ceasefire plan that involves disarming Hamas, rebuilding the war-ravaged territory and establishing ...
Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data ...
A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase modulators” was published by researchers at Nanyang Technological University, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results